Emmaus Life Sciences Expresses Concerns Over Inaccuracies in Draft Report Issued by ICER (Institute for Clinical and Economic Review)
EMMAUS LIFE SCIENCES INC (EMMA)
Company Research
Source: GlobeNewswire
TORRANCE, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, responded today to the draft evidence report by ICER dated January 23, 2020 examining the effectiveness and value of Crizanlizumab, Voxelotor, and L-glutamine in treating sickle cell disease (SCD). After reviewing the draft report, Emmaus is very concerned about the negative impact the numerous inaccuracies and misinformation will have on the SCD community including patients, investigators and manufacturers. The following table summarizes the results of Emmaus’ Phase III clinical trial of Endari® (L-glutamine oral powder): Descriptive Results Sickle Cell Crises (median)Acute Chest Syndrome (occurrence)Hospitalizations (median)Cumulative Days in Hospital (median)L-glutamine38.6%26.5Placebo423.1%311Difference from placebo25%63%33%41%P-value for between group difference0.0052a0.0028a0.0045a0.022b Cochran Mantel Haenszel (CMH) with modified ridi
Show less
Read more
Impact Snapshot
Event Time:
EMMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EMMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EMMA alerts
High impacting EMMAUS LIFE SCIENCES INC news events
Weekly update
A roundup of the hottest topics
EMMA
Sec Filings
- 4/1/24 - Form NT
- 2/29/24 - Form 4
- 2/26/24 - Form 8-K
- EMMA's page on the SEC website